Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab

Neuro-Oncology

Volumn 19, Issue 12, 2017, Pages 1688-1697

  Grossmann, Patrick ^a,b   Narayan, Vivek ^a   Chang, Ken ^a   Rahman, Rifaquat ^a   Abrey, Lauren ^c   Reardon, David A ^b   Schwartz, Lawrence H ^d   Wen, Patrick Y ^b   Alexander, Brian M ^a   Huang, Raymond ^a   Aerts, Hugo J W L ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

bevacizumab; glioblastoma; radiomics; recurrent; survival

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; GADOLINIUM PENTETATE MEGLUMINE; IRINOTECAN; TEMOZOLOMIDE; ANGIOGENESIS INHIBITOR; CONTRAST MEDIUM;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; FEMALE; FOLLOW UP; GLIOBLASTOMA; HAZARD RATIO; HUMAN; IMAGE SEGMENTATION; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK ASSESSMENT; VERY ELDERLY; BRAIN TUMOR; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; IMAGE PROCESSING; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SECONDARY; SURVIVAL RATE; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; BIOMARKERS; BRAIN NEOPLASMS; CONTRAST MEDIA; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 85027870562     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nox092     Document Type: Article

References (53)

1. Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 2015;17(Suppl 4):iv1-iv62.
2. Thakkar JP, Dolecek TA, Horbinski C, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014;23(10):1985-1996.
3. Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol. 2014;16(7):896-913.
4. Stupp R, Mason WP, van den Bent MJ, et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
5. Stupp R, Hegi ME, Mason WP, et al.; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466.
6. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391-400.
7. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
8. Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology. 2014;271(1):200-210.
9. Wick W, Stupp R, Gorlia T, et al. Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma. ASCO Meeting Abstracts. 2016;34(15-suppl):2019.
10. Wick W, Brandes AA, Gorlia T, et al. LB-05: phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma: The EORTC 26101 trial. Neuro Oncol. 2015;17(suppl 5):v1.
11. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699-708.
12. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapytemozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709-722.
13. Chang K, Zhang B, Guo X, et al. Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab. Neuro Oncol. 2016;18(12):1680-1687.
14. Ellingson BM, Sahebjam S, Kim HJ, et al. Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma. AJNR Am J Neuroradiol. 2014;35(4):673-679.
15. Pope WB, Kim HJ, Huo J, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009;252(1):182-189.
16. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016;278(2):563-577.
17. Aerts HJ, Velazquez ER, Leijenaar RT, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006.
18. Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48(4):441-446.
19. Kim H, Zheng S, Amini SS, et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 2015;25(3):316-327.
20. Kim J, Lee IH, Cho HJ, et al. Spatiotemporal evolution of the primary glioblastoma genome. Cancer Cell. 2015;28(3):318-328.
21. Macyszyn L, Akbari H, Pisapia JM, et al. Imaging patterns predict patient survival and molecular subtype in glioblastoma via machine learning techniques. Neuro Oncol. 2016;18(3):417-425.
22. Kickingereder P, Burth S, Wick A, et al. Radiomic profiling of glioblastoma: identifying an imaging predictor of patient survival with improved performance over established clinical and radiologic risk models. Radiology. 2016;280(3):880-889.
23. Yang D, Rao G, Martinez J, Veeraraghavan A, Rao A. Evaluation of tumor-derived MRI-texture features for discrimination of molecular subtypes and prediction of 12-month survival status in glioblastoma. Med Phys. 2015;42(11):6725-6735.
24. Cui Y, Tha KK, Terasaka S, et al. Prognostic imaging biomarkers in glioblastoma: development and independent validation on the basis of multiregion and quantitative analysis of MR images. Radiology. 2015;1278(2):546-553.
25. Itakura H, Achrol AS, Mitchell LA, et al. Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct molecular pathway activities. Sci Transl Med. 2015;7(303):303ra138.
26. Gevaert O, Mitchell LA, Achrol AS, et al. Glioblastoma multiforme: exploratory radiogenomic analysis by using quantitative image features. Radiology. 2014;273(1):168-174.
27. Rios Velazquez E, Aerts HJ, Gu Y, et al. A semiautomatic CT-based ensemble segmentation of lung tumors: comparison with oncologists' delineations and with the surgical specimen. Radiother Oncol. 2012;105(2):167-173.
28. Huang RY, Rahman R, Hamdan A, et al. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab. Cancer. 2013;119(19):3479-3488.
29. Le S, Josse J, Husson F. FactoMineR: an R package for multivariate analysis. J Stat Softw. 2008;25(1):1-18.
30. R Development Core Team. R Development Core Team (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http:// www.R-project.org.
31. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361-387.
32. Schroder MS, Culhane AC, Quackenbush J, Haibe-Kains B. survcomp: an R/Bioconductor package for performance assessment and comparison of survival models. Bioinformatics. 2011;27(22):3206-3208.
33. Fawcett T. An introduction to ROC analysis. Pattern Recognit Lett. 2006;27(8):861-874.
34. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004;23(13):2109-2123.
35. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995;57(1):289-300.
36. Bauer DF. Constructing confidence sets using rank statistics. J Am Stat Assoc. 1972;67(339):687-690.
37. Peng H, Long F, Ding C. Feature selection based on mutual information: criteria of max-dependency, max-relevance, and min-redundancy. IEEE Trans Pattern Anal Mach Intell. 2005;27(8):1226-1238.
38. Breiman L, Friedman J, Stone CJ, Olshen RA. Classification and Regression Trees. Belmont, CA: Wadsworth International Group; 1984.
39. Fu P, He YS, Huang Q, et al. Bevacizumab treatment for newly diagnosed glioblastoma: systematic review and meta-analysis of clinical trials. Mol Clin Oncol. 2016;4(5):833-838.
40. Schaub C, Tichy J, Schäfer N, et al. Prognostic factors in recurrent glioblastoma patients treated with bevacizumab. J Neurooncol. 2016;129(1):93-100.
41. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Mischel PS, Pope WB. Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011;13(4):401-409.
42. Grossman R, Shimony N, Shir D, et al. Dynamics of FLAIR volume changes in glioblastoma and prediction of survival. Ann Surg Oncol. 2017;24(3):794-800.
43. Schmainda KM, Prah M, Connelly J, et al. Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. Neuro Oncol. 2014;16(6):880-888.
44. Huang RY, Rahman R, Hamdan A, et al. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab. Cancer. 2013;119(19):3479-3488.
45. Pope WB, Qiao XJ, Kim HJ, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol. 2012;108(3):491-498.
46. Kickingereder P, Gotz M, Muschelli J, et al. Large-scale radiomic profiling of recurrent glioblastoma identifies an imaging predictor for stratifying anti-angiogenic treatment response. Clin Cancer Res. 2016;22(23):5765-5771.
47. Rahman R, Hamdan A, Zweifler R, et al. Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab. J Neurooncol. 2014;119(1):149-158.
48. Pope WB, Qiao XJ, Kim HJ, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol. 2012;108(3):491-498.
49. Colavolpe C, Chinot O, Metellus P, et al. FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan. Neuro Oncol. 2012;14(5):649-657.
50. Grossmann P, Gutman DA, Dunn WD Jr, Holder CA, Aerts HJ. Imaginggenomics reveals driving pathways of MRI derived volumetric tumor phenotype features in Glioblastoma. BMC Cancer. 2016;16:611.
51. Gutman DA, Dunn WD Jr, Grossmann P, et al. Somatic mutations associated with MRI-derived volumetric features in glioblastoma. Neuroradiology. 2015;57(12):1227-1237.
52. Abdulla S, Saada J, Johnson G, Jefferies S, Ajithkumar T. Tumour progression or pseudoprogression A review of post-treatment radiological appearances of glioblastoma. Clin Radiol. 2015;70(11):1299-1312.
53. Koch CJ, Lustig RA, Yang XY, et al. Microvesicles as a biomarker for tumor progression versus treatment effect in radiation/temozolomidetreated glioblastoma patients. Transl Oncol. 2014;7(6):752-758.